Rohto Pharmaceutical Co.Ltd. (RPHCF) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rohto Pharmaceutical Co.L...

    PNK: RPHCF · Real-Time Price · USD
    20.09
    -6.54 (-24.56%)
    At close: Jan 24, 2025, 9:00 PM

    Rohto Pharmaceutical Income Statement

    Financials in JPY. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
    Period Ending Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
    Revenue
    		 69.68B 519.43M 446.34M 423.79M 469.69M 502.8M 401.01M 384.81M 456.95M 460.38M 437.56M 381.25M 465M 46.62B 44.28B 38.77B
    Cost of Revenue
    		 29.81B 212.11M 191.43M 176.68M 199.55M 206.54M 174.54M 167.56M 190.3M 187.9M 184.16M 165.03M 193.88M 18.86B 17.63B 16.71B
    Gross Profit
    		 39.87B 307.32M 254.91M 247.11M 270.14M 296.26M 226.47M 217.25M 266.65M 272.48M 253.39M 216.22M 271.11M 27.75B 26.65B 22.06B
    Operating Income
    		 4.79B 101.32M 63.09M 79.94M 40.36M 94M 53.65M 61.08M 46.56M 84.06M 64.11M 54.14M 46.04M 6.28B 6.9B 3.58B
    Interest Income
    		 428M 3M 2.38M 2.19M 2.4M 1.62M 1.23M 1.86M 764K 903.34K 871.45K 666.73K 733.03K 76M 91M 93M
    Pretax Income
    		 4.95B 99.4M 68.94M 84.81M 35.85M 89.33M 56.33M 71.1M 36.18M 84.33M 66.74M 57.76M 54.14M 7.97B 6.06B 2.69B
    Net Income
    		 4.78B 67.77M 50.22M 62.98M 35.67M 64.39M 42.81M 51.5M 33.56M 53.65M 54.14M 42.63M 51.21M 4.91B 4.24B 1.75B
    Selling & General & Admin
    		 n/a 186.46M 170.7M 149.8M 203.67M 184.97M 151.23M 139.59M 199.07M 171.57M 167.82M 145.01M 204.92M n/a n/a n/a
    Research & Development
    		 n/a 19.54M 21.12M 17.37M 26.12M 17.3M 21.59M 16.57M 21.02M 16.84M 21.46M 17.06M 20.15M n/a n/a n/a
    Other Expenses
    		 35.08B 263M 252M 180M -355M -510M 288M 514M -52M 144M 36M 118M -0.00 36M -58M 134M
    Operating Expenses
    		 35.08B 206M 191.82M 167.17M 229.78M 202.26M 172.82M 156.16M 220.09M 188.42M 189.28M 162.08M 225.08M 21.47B 19.75B 18.49B
    Interest Expense
    		 16M 503.18K 421.6K 318.69K 398.93K 541.3K 455.86K 419.75K 1.07M 390.87K 368.34K 288.31K 434.39K 32M 33M 32M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a 46.47B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Cost & Expenses
    		 64.89B 418.11M 383.25M 343.85M 429.33M 408.81M 347.36M 323.72M 410.39M 376.32M 373.45M 327.11M 418.96M 40.34B 37.38B 35.2B
    Income Tax Expense
    		 84M 30.62M 18.26M 20.71M 1.26M 24.14M 13.38M 19.07M 2.89M 29.62M 12.4M 14.97M 2.8M 3.06B 1.82B 933M
    Shares Outstanding (Basic)
    		 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M n/a n/a 228.14M
    Shares Outstanding (Diluted)
    		 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M n/a n/a 228.81M
    EPS (Basic)
    		 20.95 0.30 0.22 0.28 0.16 0.28 0.19 0.23 0.15 0.24 0.24 0.19 0.22 n/a n/a 7.66
    EPS (Diluted)
    		 20.89 0.30 0.22 0.28 0.16 0.28 0.19 0.23 0.15 0.23 0.24 0.19 0.22 n/a n/a 7.64
    EBITDA
    		 4.96B 14.1B 10.37B 12.29B 4.82B 11.79B 8.22B 9.71B 4.53B 9.75B 7.47B 6.46B 6.03B 6.43B 7.15B 3.97B
    EBIT
    		 4.96B 14.1B 10.37B 12.29B 4.82B 11.79B 8.22B 9.71B 4.53B 9.75B 7.47B 6.46B 6.03B 8.01B 6.09B 2.72B
    Depreciation & Amortization
    		 342M 15.47M 14.13M 43.28K 43.81K -39.59K 122.08K 41.58K 54.88K 27.08K 86.06K 60.46K 71.39K 54K 55.81K 55.21K

    Add to Watchlist